C4 Therapeutics, Inc. CCCC
At closeNov 5, 2026, 7:37 PM EST
After hours · Nov 5, 7:37 PM ET
- YTD
- +54.45%
- 1 year
- +24.47%
- Market cap
- 362.92M
- Revenue (ttm)
- 33.67M
- EPS (ttm)
- -0.86
- Shares out
- 70.59M
- Forward P/E
- -2.37
- YTD return
- +54.45%
- 1-year return
- +24.47%
- Volume
- 3.68M
- Avg volume
- 2.41M
- Open
- 3.08
- Previous close
- 3.12
- Day's range
- 2.91 – 3.22
- 52-week range
- 1.71 – 4.67
- Beta
- 3.06
- Analysts
- Buy
- Price target
- 15.00 (+408.5%)
- Earnings date
- Aug 1, 2024
5D -0.37 (-11.14%)
Key statistics
- Enterprise value
- 90.28M
- PEG ratio
- 0.00
- Price / sales
- 8.51
- Price / book
- 1.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 38.70%
- Free cash flow
- -41.84M
- Total cash
- 255.64M
- Total debt
- 67.09M
- Return on equity
- -46.00%
- Short % of float
- 13.71%
- 50-day average
- 5.06
- 200-day average
- 5.96
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 15.00
- Target (high)
- 39.00
- Strong buy1
- Buy5
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 1, 2024
Expected Aug 1, 2024. Consensus EPS estimate -0.44.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.40 | -0.35 | +0.05 | +12.50% |
| Aug 1, 2024 | Jun 1, 2024 | -0.37 | -0.26 | +0.11 | +29.73% |
| Aug 1, 2024 | Jun 1, 2024 | -0.37 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.41 | -0.41 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.41 | — | — | — |
| Feb 22, 2024 | Dec 1, 2023 | -0.67 | -0.68 | -0.01 | -1.49% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | up | Equal-Weight | Overweight |
| Nov 18, 2024 | Stephens & Co. | init | — | Equal-Weight |
| Aug 6, 2024 | BMO Capital | reit | Outperform | Outperform |
| May 9, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| May 9, 2024 | Stifel | main | Buy | Buy |
| Feb 26, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- c4therapeutics.com
News
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates 
C4 Therapeutics Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $8.468M Miss $8.514M Estimate 
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights 
C4 Therapeutics to Participate in Upcoming November Investor Conferences 
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release 
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders 
Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11 
Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey 
Insmed Appoints Two New Directors to Its Board
Your note
Sign in to keep a note on CCCC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS KENDRA | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 6, 2024 | 84,439 |
| ANDERSON KENNETH CARL | Director | Stock Award(Grant) | Sep 30, 2024 | 320,418 |
| BOYLE SCOTT N | Officer | Conversion of Exercise of derivative security | Nov 6, 2024 | 56,567 |
| DUBIN GLENN R. | Director | Stock Award(Grant) | Mar 31, 2024 | 812,682 |
| FISHER STEWART | Officer | Conversion of Exercise of derivative security | Sep 15, 2024 | 130,710 |
| GROGAN DONNA ROY M.D. | Director | Stock Award(Grant) | Sep 30, 2024 | 28,942 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynx1 Capital Management Lp | 9.75% | 6,880,527 | 27.93M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 9.36% | 6,603,996 | 26.81M | Sep 29, 2024 |
| Wasatch Advisors LP | 8.04% | 5,677,368 | 23.05M | Sep 29, 2024 |
| Blackrock Inc. | 6.93% | 4,890,935 | 19.86M | Sep 29, 2024 |
| RA Capital Management, L.P. | 6.91% | 4,878,000 | 19.80M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 6.20% | 4,377,900 | 17.77M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Ultra Growth Fund | 3.70% | 2,609,942 | 10.60M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.03% | 2,135,945 | 8.67M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.34% | 1,653,493 | 6.71M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.17% | 1,534,793 | 6.23M | Oct 30, 2024 |
| Wasatch Microcap Fund | 1.76% | 1,242,144 | 5.04M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.12% | 789,707 | 3.21M | Sep 29, 2024 |